ILB-2107

N/A

Report date: 2024/10/15 17:46:08

Base Information

Drug NameILB-2107
Drug Alias NameILB-2107
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionTumor necrosis factor receptor superfamily member 4 inhibitors
TargetsTumor necrosis factor receptor superfamily member 4
Therapy Area/IndicationsAutoimmune Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesInnolake Biopharm (Hangzhou) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesInnolake Biopharm (Hangzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsAutoimmune Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A